Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients

Journal of Clinical Psychiatry

Volumn 66, Issue 4, 2005, Pages 450-454

  Sharpley, Ann L ^a   Attenburrow, Mary E J ^a   Hafizi, Sepehr ^a   Cowen, Philip J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; FLUOXETINE; LITHIUM CARBONATE; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ACUTE DRUG ADMINISTRATION; ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; NONREM SLEEP; OPEN STUDY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REM SLEEP; SCHIZOPHRENIA; SLOW WAVE SLEEP; STATISTICAL ANALYSIS; VOLUNTEER;

EID: 17844406880     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0407     Document Type: Article

References (18)

1. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001;62:135-142
2. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000;61 (suppl 1):26-32
3. Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 2002;63:95-103
4. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60:256-259
5. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134
6. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatrie disorders. Neuropsychopharmacology 2003;28:402-412
7. 2C receptors in the control of central dopamine function. Trends Pharmacol Sci 2001;22:229-232
8. Rues VI. Olanzapine: a novel atypical neuroleptic agent. Lancet 1997;349:1264-1265
9. 2C receptors in vivo. Biol Psychiatry 2000;47:468-470
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
11. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles, Calif: UCLA Brain Information Service/Brain Research Institute; 1968
12. Sharpley AL, Williamson DJ, Attenburrow MEJ, et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996;126:50-54
13. Sharpley AL, McGavin CL, Whale R, et al. Antidepressant-like effect of hypericum perforatum (St John's wort) on the sleep polysomnogram. Psychopharmacology (Berl) 1998;139:286-287
14. Sharpley AL, Cowen PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry 1995;37:85-98
15. Sharpley AL, Bhagwagar Z, Hafizi S, et al. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry 2003;64:192-196
16. 2C receptors. Neuropharmacology 1994;33:467-471
17. Janssen P, Niemegeers C, Awouters F, et al. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-693
18. Hairston IS, Knight RT. Neurobiology: sleep on it [comment]. Nature 2004;430:27-28